Learn everything you need to know about Dofetilide-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

FDA's requirements for the use of dofetilide are described, and one hospital's strategy for meeting the requirements is discussed. Dofetilide is a specific class III antiarrhythmic agent approved for ...

Atrial fibrillation is common, affecting approximately 5.2 million patients in 2010 in the United States, and this is projected to increase to 12.1 million in 2030. Tanvi Patil Stacey Zysk Kezia ...

Review the side-effects of Dofetilide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Please provide your email address to receive an email when new articles are posted on . Nearly 20% of patients with atrial fibrillation who were hospitalized to start dofetilide had to discontinue the ...

Pfizer’s Tikosyn (dofetilide) has been available since 1999 to help treat patients with irregular heartbeats. Now, years after the drug has gone generic, scientists at Georgetown University have found ...

Findings reported in The American Journal of Pathology suggest dofetilide may counteract pathological changes in potassium channels associated with pulmonary arterial hypertension in humans and rats ...

Tikosyn (dofetilide) is a prescription oral capsule that’s used to treat atrial fibrillation and atrial flutter. Tikosyn’s cost may depend on factors such as your dosage, whether you have health ...

MONTREAL, Aug. 25, 2023 /CNW/ - Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in individuals with ...

For dofetilide to be available at any institution, three FDA requirements must be fulfilled. First, the institution must complete a staff education process and submit an Education Confirmation Form ...

High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a potentially fatal disease caused by obstruction of blood flow in the lungs. A new study in The American Journal ...